BioCentury
ARTICLE | Clinical News

S: Phase II/III suspended enrollment

April 18, 2011 7:00 AM UTC

Merck and Intercell suspended enrollment in a double-blind, placebo-controlled, international Phase II/III trial of V710 pending further analyses of the vaccine's benefit-risk profile. The decision wa...